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  EVIDENCE-BASED ANSWER 
Ferrous salt preparations (ferrous sulfate, ferrous gluconate, and ferrous fumarate) are equally tolerable. (Grade 
of recommendation: A, based on randomized controlled trial.) Controlled-release iron preparations cause less 
nausea and epigastric pain than conventional ferrous sulfate (grade of recommendation: A, based on 
randomized controlled trials), although the discontinuation rates between the 2 iron formulations were similar. 
Ferrous sulfate remains the standard first-line treatment of iron-deficiency anemia given its general tolerability, 
effectiveness, and low cost. 
  EVIDENCE SUMMARY 
A randomized, double-blinded, placebo-controlled study in 1496 subjects examined side-effect rates of 3 iron 
salt formulations using equal dosages of elemental iron (Table).1 Gastrointestinal (GI) side-effect rates were not 
significantly different. The side-effect rate in the ferrous sulfate group (23%) was significantly different from that 
of the placebo group (14%); thus, for every 11 patients treated with ferrous sulfate, 1 patient would have GI side 
effects attributable to the iron salt (number needed to harm [NNH] = 11). 
Two formulations—controlled-release iron preparations and polysaccharide–iron complexes—decrease the 
amount of iron presented to the proximal GI tract. Three large randomized trials assessed tolerability of 
controlled-release iron preparations compared with ferrous sulfate.2–4 The only double-blinded study found a 
lower rate of nausea and epigastric pain in the controlled-release iron formulation among 1376 blood donors 
receiving 200 mg/day elemental iron (3.3% vs 6.4%, P < .05, NNH = ~32).2 A nonblinded randomized trial of 
543 non-anemic adult patients taking 50 mg/day elemental iron also found a lower rate of stomach-related side 
effects in the controlled-release group (12.2% vs 27.2%, P < .001, NNH = ~7).3 However, none of the 3 studies 
showed a difference in the discontinuation rates between the 2 iron formulations. Comparative constipation 
rates among the trials were conflicting. 
Two small, nonblinded, randomized trials of polysaccharide–iron complexes reported conflicting results. A study 
of 159 subjects found fewer subjects discontinuing the polysaccharide–iron complex taken with meals than 
ferrous sulfate taken on an empty stomach.5 A study of 60 subjects taking both preparations on an empty 
stomach found no difference in side-effect rates.6 Two small, randomized, blinded studies found no difference in 
rates of GI side effects between carbonyl iron and ferrous sulfate.7,8 
 
TABLE 
Representative average wholesale prices* for various iron supplement formulations 
Iron supplement 
group 
Generic or 
brand name 
Dosage 
Cost of 1-
month 
course 
Ferrous salts Ferrous sulfate 
(generic) 
Tablet: 325 mg 
po tid 
$0.63 to 
$5.11 (90 
tabs) 
Ferrous 
fumarate 
(generic) 
Tablet: 300 mg 
(99 mg iron) 
po bid 
$1.80 (60 
tabs) 
Ferrous 
gluconate 
(generic) 
Tablet: 325 mg 
(36 mg iron) 
po tid 
$2.70 to 
$5.00 (90 
tabs) 
Controlled-release Slow FE 
(Novartis) 
Tablet: 160 mg 
(50 mg iron) 
po tid 
$18.92 (90 
tabs) 
Ferro-Grad-500 
(Abbott) 
Tablet: 105 mg 
iron po bid 
$31.84 (60 
tabs) 
Polysaccharide–iron 
complex 
Niferex-150 
(Schwarz 
Pharma) 
Capsule: 150 
mg iron po qd 
$10.50 (30 
caps) 
Carbonyl iron Feosol 
(SmithKline 
Beecham) 
Tablet: 50 mg 
iron po tid 
$18.38 (90 
tabs) 
*2001 Drug Topics, Red Book. Daily dosages given here deliver 150 to 210 mg of 
elemental iron and are for comparison of average costs. Actual dosage should be 
adjusted according to the calculated need for iron replacement and the results of 
laboratory monitoring. 
  RECOMMENDATIONS FROM OTHERS 
Wintrobe’s Clinical Hematology9 and Williams Hematology10 recommend ferrous sulfate as the standard oral 
iron preparation, and assert that claims of improved tolerability of one oral iron preparation over another have 
not been substantiated. 
Clinical Commentary by Andrea Gordon, MD, at http://www.fpin.org. 
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